Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000053/S141

AMS 800 Artificial Urinary Sphincter (AUS)

Boston Scientific Corp · Decision date Feb 25, 2026

FDA DECISIONP000053/S141

What did the FDA decide?

FDA records P000053/S141 as a supplement to PMA P000053, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 25, 2026.

FDA approval order statement

approval to add a new supplier for a cuff backing raw material
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Feb 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P000053/S141
Regulatory pathway
PMA supplement
Product code
EZY
Decision code
OK30
Decision date
Feb 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, incontinence, mechanical/hydraulic.

Product code
EZY
FDA device class
3

For the original device and its historical approval scope, see PMA P000053. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P000053 · Original PMA

    AMS SPHINCTER 800 URINARY CONTROL SYSTEM

  2. P000053/S141 received

    Application receipt date recorded by FDA.

  3. P000053/S141 · FDA decision

    30-Day Notice

  4. P000053/S142 · Related supplement

    AMS 800 Artificial Urinary Sphincter (AUS)

Timeline entries are records held by MedtechLedger for P000053. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000053

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalJun 14, 2001FDA
Boston Scientific CorpPMA supplementSep 14, 2026FDA

Explore the linked device profile

Other records with product code EZY

Product / regulatory recordCompanyPathwayDecision dateSource
Uromedica, Inc.PMA supplementFeb 11, 2026FDA
Uromedica, Inc.PMA supplementJan 28, 2026FDA
Uromedica, Inc.PMA supplementOct 3, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
100 Boston Scientific Way, Marlboro, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records